MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
Go back to MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy| Miracle Applications Corp (NASDAQ: MIRA) | Delayed: 0.96 +0.01 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.95 | 52 Week High | $0.04 | |||
| Open | $0.97 | 52 Week Low | $0.00 | |||
| Day High | $0.97 | P/E | N/A | |||
| Day Low | $0.95 | EPS | $0.00 | |||
| Volume | 124,893 | |||||
